Scientists have shown that treating mice with an antibody that blocks the interaction between APOE proteins sprinkled within Alzheimer's disease plaques and the LILRB4 receptor on microglia cells activates them to clean up damaging plaques in the brain.
The approach could have implications beyond Alzheimer's. Toxic clumps of brain proteins are features of many neurodegenerative conditions, including Parkinson's disease, amyotrophic lateral sclerosis and Huntington's disease. Encouraged by the study results, researchers are exploring other potential immunotherapies -- drugs that harness the immune system -- to remove junk proteins from the brain that are believed to advance other diseases.
For reasons that are still unknown, the researchers found that, in mice and people with Alzheimer's disease, microglia that surround plaques produce and position LILRB4 on their cell surface, which inhibits their ability to control damaging plaque formation upon binding to APOE.
Drugs that target amyloid plaques directly can cause a potentially serious side effect. In Alzheimer's patients, amyloid proteins build up on the walls of the arteries in the brain as well as other parts of brain tissue. Removing plaques from brain blood vessels can induce swelling and bleeding, a side effect known as ARIA. This side effect is seen in some patients receiving lecanemab, a drug approved by the Food and Drug Administration to treat Alzheimer's.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: MedicineNet - 🏆 575. / 51 Read more »
Source: Newsweek - 🏆 468. / 52 Read more »